Detalhe da pesquisa
1.
Spatial predictors of immunotherapy response in triple-negative breast cancer.
Nature
; 621(7980): 868-876, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37674077
2.
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
N Engl J Med
; 388(18): 1645-1656, 2023 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37133584
3.
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
PLoS Genet
; 19(1): e1010563, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36595552
4.
Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content.
Cell
; 140(1): 62-73, 2010 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-20074520
5.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
N Engl J Med
; 384(25): 2394-2405, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34081848
6.
Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis.
Breast Cancer Res Treat
; 191(1): 137-145, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34609640
7.
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study.
Mod Pathol
; 35(10): 1362-1369, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35729220
8.
Corrigendum: Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells.
Nat Immunol
; 16(3): 326, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25689446
9.
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients.
Anticancer Drugs
; 33(1): e628-e634, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407044
10.
Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial.
Lancet Oncol
; 22(5): 597-608, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33845035
11.
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Lancet Oncol
; 22(4): 476-488, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33721561
12.
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.
Br J Cancer
; 125(1): 38-47, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33828257
13.
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).
Breast Cancer Res Treat
; 190(2): 265-275, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34476645
14.
Metaplastic breast cancer: Prognostic and therapeutic considerations.
J Surg Oncol
; 123(1): 61-70, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33047318
15.
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.
J Pathol
; 250(5): 667-684, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32129476
16.
Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Breast Cancer Res
; 22(1): 107, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33059724
17.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
N Engl J Med
; 377(2): 122-131, 2017 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28581356
18.
Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast.
Mod Pathol
; 33(6): 1065-1077, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31925342
19.
Post-radiotherapy vascular lesions of the breast: immunohistochemical and molecular features of 74 cases with long-term follow-up and literature review.
Histopathology
; 77(2): 293-302, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32043616
20.
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
Lancet Oncol
; 20(3): 371-382, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30765258